- Home
- HTFL vs AMLX Comparison
HTFL vs AMLX Comparison
Compare HTFL & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTFL | AMLX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HTFL | AMLX |
|---|---|---|
| Price | $29.63 | $14.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $38.20 | $21.56 |
| AVG Volume (30 Days) | ★ 969.0K | 948.4K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $27.66 | N/A |
| Revenue Next Year | $23.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $20.13 | $4.64 |
| 52 Week High | $41.22 | $18.61 |
Technical Indicators
Market Signals| Indicator | HTFL | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 36.65 |
| Support Level | $28.60 | $13.02 |
| Resistance Level | $32.81 | $15.37 |
| Average True Range (ATR) | 1.57 | 0.86 |
| MACD | -0.28 | -0.32 |
| Stochastic Oscillator | 28.07 | 0.00 |
Price Performance
Historical ComparisonAbout HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.